Alzheimer's biomarkers
What are biomarkers?
Blood-based biomarkers for Alzheimer's
Protecting your brain
Diagnosis & disease progression
What's a biomarker?
Biomarkers are measurable, biological characteristics that signal whether things are normal or abnormal in the body.
Blood tests for biomarker proteins
Images from retinal scans
Apps that assess vocal signatures
In the case of Alzheimer's disease, biomarkers might be present in the blood, the eye, or even detectable in someone's gait or speech patterns.
Return
Next
Alzheimer's protein biomarkers
The most commonly referenced biomarkers for Alzheimer's are two problematic proteins: beta-amyloid and tau.
These can be evident in the blood or cerebrospinal fluid, offering clues for early detection. They are not stand-alone diagnostic tools, and a full clinical evaluation is needed to confirm an Alzheimer's diagnosis.
Return
Next
Alzheimer's biomarkers: Beta-amyloid
Beta-amyloid proteins are peptides in the brain that do important work for our synaptic plasticity and memory function. But they are also one of the key biomarkers for Alzheimer's.
- The first "red flag": Build-up begins more than a decade before Alzheimer’s symptoms appear.
- Not a guarantee: Not everyone with beta-amyloid plaques develops Alzheimer’s.
- Early diagnosis: Advanced tests can detect these plaques before symptoms, identifying those at risk.
- Supporting data: If someone shows Alzheimer’s symptoms, plaques can help confirm the diagnosis.
Return
Next
Alzheimer's biomarkers: Tau
In a healthy brain, tau proteins act as highways within brain cells, helping to transport necessary nutrients and other molecules. In the brains of people with Alzheimer’s, however, tau proteins begin to stick together, forming tangles that disrupt the normal function of neurons.
As of now, blood tests that measure certain types of tau protein are generally more accurate than tests for beta-amyloid at tracking disease progression.
Return
Next
Biomarkers in spinal fluid
Cerebrospinal fluid (CSF) is like a liquid fingerprint — and it can carry clues about health, including markers of Alzheimer's. The presence of protein biomarkers in CSF can flag abnormal brain activity, like inflammation or cell damage.
CSF biomarker tests
CSF is drawn via a lumbar puncture (spinal tap) to measure beta-amyloid or tau.
Return
Next
Biomarkers in blood
Neurologists might also look for these proteins in the blood. Blood tests for beta-amyloid and tau are relatively new and while they can't definitively diagnose Alzheimer's on their own, they can add supporting evidence to the diagnostic process.
Blood biomarker tests
Blood is taken from a vein, usually in the arm, just like in routine bloodwork.
Return
Next
What Alzheimer's blood tests look for
Neurology researcher Wagner Brum studies amyloid and tau in Alzheimer's.
An expert's perspective
“We know that having high blood sugar is bad, and we know that having high cholesterol is bad, but with amyloid in the fluids, it’s the opposite. Having low [amounts] is bad because it means that it is accumulating into blocks in the brain.”
Wagner S. Brum
Federal University of Rio Grande do Sul
Read more
Return
Next
Biomarkers in brain scans
Beta-amyloid and tau aren't only detectable in cerebrospinal fluid and blood: They can also appear in images via one of these types of brain scans. Brain imaging helps neurologists identify abnormal brain structures or changes during the diagnostic process, monitor disease progression over time, and evaluate the effectiveness of treatments.
Amyloid PET scans
Tau PET scans
FDG PET scans
Return
Next
Brain atrophy in Alzheimer's
As Alzheimer's progresses, neurons in the brain die off. This physical change can be tracked with various imaging tools, like PET scans, helping doctors understand disease progression and severity.
Healthy brain
Alzheimer's brain
Return
Next
Future biomarkers
Scientists are discovering and studying new types of biomarkers that could mean earlier and more accurate dementia diagnosis, well before symptoms appear. Early detection gives patients more opportunity for lifestyle modifications and treatments that could help delay the onset of symptoms.
Vocal signatures
Wearables data
Retinal biomarkers
Return
Next
Why early detection matters
Dr. Peter Snyder is studying new retinal scan technology that may be able to identify markers of Alzheimer's disease, potentially allowing detection as early as 20 years before symptoms appear.
An expert's perspective
“It's so much easier to protect [the brain] than to try to reverse time and go back. ... I believe that we're not going to be able to slow progression of the disease — we're not going to be able to develop a therapy that really is effective — unless we intervene earlier than... we've attempted so far."
Peter J. Snyder
Professor of Biomedical & Pharmaceutical Sciences University of Rhode Island
watch the video
Return
Next
Genetic biomarkers
Variants of ApoE4 carry different levels of genetic risk for Alzheimer's
Gene
Variant
Significance
Reduced risk
E2
APOE
Neutral risk
E3
(Alz. gene)
Higher risk
E4
Return
Next
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
Return
Analyze speech patterns, vocal rhythms, and linguistic features to detect subtle changes that may flag cognitive decline.
Amyloid PET Scans
detect beta-amyloid plaques in the brain. They use radiotracers that bind to amyloid proteins, allowing visualization of plaque deposits.
FDG PET Scans
assess glucose metabolism in the brain. Reduced glucose uptake in specific brain regions (e.g., the temporal and parietal lobes) is a biomarker for neuronal damage in Alzheimer’s and other dementias.
Tau PET scans
detect tau tangles in the brain (still in research development). These scans use radiotracers that bind specifically to tau deposits.
Track physiological and behavioral changes (walking stability, heart rate variability), for early signs of Alzheimer's.
Analyze structure and vasculature in the eye for early signs of Alzheimer's.
Alzheimer's Biomarkers
Deborah Kan
Created on November 13, 2025
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Timeline Lines Mobile
View
Major Religions Timeline
View
Timeline Flipcard
View
Timeline video
View
Images Timeline Mobile
View
Sport Vibrant Timeline
View
Decades Infographic
Explore all templates
Transcript
Alzheimer's biomarkers
What are biomarkers?
Blood-based biomarkers for Alzheimer's
Protecting your brain
Diagnosis & disease progression
What's a biomarker?
Biomarkers are measurable, biological characteristics that signal whether things are normal or abnormal in the body.
Blood tests for biomarker proteins
Images from retinal scans
Apps that assess vocal signatures
In the case of Alzheimer's disease, biomarkers might be present in the blood, the eye, or even detectable in someone's gait or speech patterns.
Return
Next
Alzheimer's protein biomarkers
The most commonly referenced biomarkers for Alzheimer's are two problematic proteins: beta-amyloid and tau.
These can be evident in the blood or cerebrospinal fluid, offering clues for early detection. They are not stand-alone diagnostic tools, and a full clinical evaluation is needed to confirm an Alzheimer's diagnosis.
Return
Next
Alzheimer's biomarkers: Beta-amyloid
Beta-amyloid proteins are peptides in the brain that do important work for our synaptic plasticity and memory function. But they are also one of the key biomarkers for Alzheimer's.
Return
Next
Alzheimer's biomarkers: Tau
In a healthy brain, tau proteins act as highways within brain cells, helping to transport necessary nutrients and other molecules. In the brains of people with Alzheimer’s, however, tau proteins begin to stick together, forming tangles that disrupt the normal function of neurons.
As of now, blood tests that measure certain types of tau protein are generally more accurate than tests for beta-amyloid at tracking disease progression.
Return
Next
Biomarkers in spinal fluid
Cerebrospinal fluid (CSF) is like a liquid fingerprint — and it can carry clues about health, including markers of Alzheimer's. The presence of protein biomarkers in CSF can flag abnormal brain activity, like inflammation or cell damage.
CSF biomarker tests
CSF is drawn via a lumbar puncture (spinal tap) to measure beta-amyloid or tau.
Return
Next
Biomarkers in blood
Neurologists might also look for these proteins in the blood. Blood tests for beta-amyloid and tau are relatively new and while they can't definitively diagnose Alzheimer's on their own, they can add supporting evidence to the diagnostic process.
Blood biomarker tests
Blood is taken from a vein, usually in the arm, just like in routine bloodwork.
Return
Next
What Alzheimer's blood tests look for
Neurology researcher Wagner Brum studies amyloid and tau in Alzheimer's.
An expert's perspective
“We know that having high blood sugar is bad, and we know that having high cholesterol is bad, but with amyloid in the fluids, it’s the opposite. Having low [amounts] is bad because it means that it is accumulating into blocks in the brain.”
Wagner S. Brum
Federal University of Rio Grande do Sul
Read more
Return
Next
Biomarkers in brain scans
Beta-amyloid and tau aren't only detectable in cerebrospinal fluid and blood: They can also appear in images via one of these types of brain scans. Brain imaging helps neurologists identify abnormal brain structures or changes during the diagnostic process, monitor disease progression over time, and evaluate the effectiveness of treatments.
Amyloid PET scans
Tau PET scans
FDG PET scans
Return
Next
Brain atrophy in Alzheimer's
As Alzheimer's progresses, neurons in the brain die off. This physical change can be tracked with various imaging tools, like PET scans, helping doctors understand disease progression and severity.
Healthy brain
Alzheimer's brain
Return
Next
Future biomarkers
Scientists are discovering and studying new types of biomarkers that could mean earlier and more accurate dementia diagnosis, well before symptoms appear. Early detection gives patients more opportunity for lifestyle modifications and treatments that could help delay the onset of symptoms.
Vocal signatures
Wearables data
Retinal biomarkers
Return
Next
Why early detection matters
Dr. Peter Snyder is studying new retinal scan technology that may be able to identify markers of Alzheimer's disease, potentially allowing detection as early as 20 years before symptoms appear.
An expert's perspective
“It's so much easier to protect [the brain] than to try to reverse time and go back. ... I believe that we're not going to be able to slow progression of the disease — we're not going to be able to develop a therapy that really is effective — unless we intervene earlier than... we've attempted so far."
Peter J. Snyder
Professor of Biomedical & Pharmaceutical Sciences University of Rhode Island
watch the video
Return
Next
Genetic biomarkers
Variants of ApoE4 carry different levels of genetic risk for Alzheimer's
Gene
Variant
Significance
Reduced risk
E2
APOE
Neutral risk
E3
(Alz. gene)
Higher risk
E4
Return
Next
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
Return
Analyze speech patterns, vocal rhythms, and linguistic features to detect subtle changes that may flag cognitive decline.
Amyloid PET Scans
detect beta-amyloid plaques in the brain. They use radiotracers that bind to amyloid proteins, allowing visualization of plaque deposits.
FDG PET Scans
assess glucose metabolism in the brain. Reduced glucose uptake in specific brain regions (e.g., the temporal and parietal lobes) is a biomarker for neuronal damage in Alzheimer’s and other dementias.
Tau PET scans
detect tau tangles in the brain (still in research development). These scans use radiotracers that bind specifically to tau deposits.
Track physiological and behavioral changes (walking stability, heart rate variability), for early signs of Alzheimer's.
Analyze structure and vasculature in the eye for early signs of Alzheimer's.